^
    5ms
    Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=5, Completed, Beijing Boren Hospital | Recruiting --> Completed | N=25 --> 5
    Trial completion • Enrollment change • CAR T-Cell Therapy
    |
    CD33 (CD33 Molecule)
    |
    cyclophosphamide • CD33 CAR T cells
    almost2years
    Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=25, Recruiting, Beijing Boren Hospital | Trial primary completion date: Sep 2022 --> Sep 2024
    Trial primary completion date • CAR T-Cell Therapy
    |
    CD33 (CD33 Molecule)
    |
    CD33 positive
    |
    cyclophosphamide • CD33 CAR T cells
    3years
    Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=25, Recruiting, Beijing Boren Hospital | Initiation date: Sep 2021 --> Apr 2021
    Clinical • Trial initiation date • CAR T-Cell Therapy
    |
    CD33 (CD33 Molecule)
    |
    CD33 positive
    |
    CD33 CAR T cells
    3years
    Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=25, Recruiting, Beijing Boren Hospital | Phase classification: P1 --> P1/2 | Trial completion date: Apr 2024 --> Sep 2024 | Initiation date: Apr 2021 --> Sep 2021 | Trial primary completion date: Apr 2022 --> Sep 2022
    Clinical • Phase classification • Trial completion date • Trial initiation date • Trial primary completion date • CAR T-Cell Therapy
    |
    CD33 (CD33 Molecule)
    |
    CD33 positive
    |
    CD33 CAR T cells
    over3years
    Phase 1 Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=20, Recruiting, Beijing Boren Hospital
    Clinical • New P1 trial • CAR T-Cell Therapy
    |
    CD33 (CD33 Molecule)
    |
    CD33 positive
    |
    CD33 CAR T cells